TLDR:
- Anbogen Therapeutics, a Taiwan-based company, raised USD 7.5M in Series A+ funding led by KGI Venture Capital.
- The funds will support the Phase II clinical trial of ABT-301 in combination with PD-1 inhibitors for treating MSS metastatic colorectal cancer.
Anbogen Therapeutics, a clinical-stage company based in Taipei, Taiwan, has successfully raised USD 7.5M in Series A+ funding. The funding round was led by KGI Venture Capital along with participation from both new and existing investors. The primary goal for the utilization of these funds is to support the Phase II clinical trial of ABT-301, a cancer therapy drug, in combination with PD-1 inhibitors for treating microsatellite stable (MSS) metastatic colorectal cancer.
Founded by Dr. Joe Shih, Anbogen Therapeutics is dedicated to developing precision anti-cancer drugs and is focused on R&D innovations to enhance the quality of life for cancer patients globally. Currently, the company has two drugs in human clinical trials – ABT-101 for non-small cell lung cancer (NSCLC) with HER2 exon20 insertion mutations and ABT-301, which is being combined with immune checkpoint inhibitors to treat metastatic colorectal cancer.
